Trade Setup Buy Target: $9.53 Sell Target: $11.45 Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company’s specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in […]
Read MorePlus, White House and Democratic negotiators made progress toward a deal on a new relief bill, ADP reported a sharp decrease in job creation in July, and Square’s earnings release was leaked ahead of schedule.
Read MoreTrade Setup Stocks found in this category are low priced stocks priced between .50 and $1, with at least 50k shares of average shares trading per day. The stocks are pausing a trend either up or down, with a new bar over the prior day open or close. These are high reward to risk stocks with the […]
Read MorePlus, democrat and republican negotiators made some progress on the next coronavirus relief bill, Ford’s Hackett is out as CEO, and Take-Two Interactive reported strong earnings results.
Read MorePlus, big tech stocks crushed earnings, $600-a-week unemployment benefits are set to expire with no agreement on a new stimulus bill in Congress, Merck is preparing to launch a large study of its experimental coronavirus treatment, and Pinterest is on the rise.
Read MoreOne analyst says this stock could gain nearly 30% in the near-term.
Read MorePlus, jobless claims rose to 1.43 million last week, Johnson & Johnson said its coronavirus vaccine candidate protected moneys from the virus with a single shot, and big tech reports earnings after the bell.
Read MorePlus, Republicans are expected to release the details of their coronavirus relief bill today, Hasbro shares are down after a 29% drop in revenue in the second quarter, and Target will be closed on Thanksgiving.
Read MoreThe market seems intent on rebounding from last week’s break in bullish momentum, with the major indices at the beginning of a new week all moving higher. That looks like another sign that investors generally want to emphasize the positive and be hopeful. Indications over the weekend that the federal government could approve a second […]
Read MoreThese 3 stocks could be the best bets in the race to develop a vaccine for COVID-19.
Read MorePlus, the U.S. ordered China to close its consulate in Houston, Nike announced a leadership shake-up, Slack filed a complaint against Microsoft with the European Commission, and United Airlines reported earnings.
Read MorePlus, it’s looking unlikely Congress will pass another coronavirus relief bill before the end of July, IBM reported an earnings beat, eBay sold its classified ads unit, and Men’s Wearhouse-parent Tailored Brands is laying off 20% of its workforce and considering closing up to 500 stores.
Read MorePlus, AstraZeneca said its coronavirus vaccine developed with Oxford University showed a promising immune response in an early study, airline stocks are down after TSA said air travel is down for the first time since April, and Amazon is up after two bullish upgrades.
Read MoreBuy Price: $5.00 or better Sell Price: TradersPro Sell Signal Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs.
Read MorePlus, jobless claims came in higher than 1 million for the seventeenth week in a row, security experts warned Russian hackers are trying to steal COVID-19 vaccine research, Morgan Stanley reported better-than-expected earnings, and Tesla shares are down after a report that its vehicle registrations were down by nearly half in the second quarter.
Read More